Output details

Mithramycin encapsulated in polymeric micelles by microfluidic technology as novel therapeutic protocol for beta-thalassemia

Significance of output:

It is estimated that the total market for nanotechnology-enabled drug delivery will rise to reach $220 billion globally by 2015. However, existing batch processes for synthesising nanostructured drug delivery systems lacks controllability of nanomaterial’s properties limiting its activity. We developed a continuous-flow microscale reactor system to formulate nanomedicine in a core-shell structure with controllable size, size distribution and drug loading efficiency, resulting in improved biological effectiveness. This was developed by integrating multidisciplinary expertise of pharmaceutical, medicine and bioengineering from an international team of UK and Italian scientists.